Biotechnology

UMeWorld's new venture in China aims to crack the SAF code with single-cell oil, a scalable feedstock that could finally break the industry's reliance on waste oils.

Medgene's new vaccine offers a first line of defense against a deadly, tick-borne parasite ravaging US cattle, highlighting a new era in rapid-response animal health tech.

Beam Therapeutics is set to unveil pivotal data for its AATD gene editor. Success could transform a disease and validate a multi-billion-dollar platform.

Samsung Bioepis's latest report reveals a thriving biosimilar market, yet deep-seated policy debates over the 340B program threaten to disrupt growth.

Viking Therapeutics' appointment of digital health veteran Dorothy Gemmell signals a pivotal shift from lab to market in the crowded weight-loss field.

With key hires in finance, regulatory, and manufacturing, Cyllene Therapeutics signals it's preparing for the big leagues. But can it deliver?

A scientific breakthrough reveals a reversible cause for sarcopenia, offering the first real hope for a drug therapy to restore strength for millions of seniors.

After a disastrous Q2 report and lowered guidance, all eyes are on Azenta's August 5th call. We dissect the key metrics and strategic shifts to watch.

A Nasdaq-listed apparel firm, facing steep losses, bets its future on a bold RMB 500M biotech deal. Is this a genius pivot or a desperate gamble in China's health boom?

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

A new report reveals a seismic shift in drug manufacturing. Forget massive factories; the real power now lies with a handful of specialists building our medical future.

Beyond cash prizes, Hainan's 'Volcano Wisdom Summit Cup' is a strategic play to lure global innovators and fast-track its Free Trade Port ambitions.

Acclaimed scientist Michael Ehlers leaves big pharma's orbit for an AI startup. It's more than a career move; it's a test of whether technology can fix our broken drug development system.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

A new AI-driven test from BRAINBox Solutions combines blood analysis and cognitive data, promising to finally replace guesswork in concussion diagnosis.

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

With $8M in new funding, Tikva Allocell is advancing a novel cell therapy that uses armored, virus-specific T cells to overcome historical barriers in cancer.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.